Use of genomic panels to determine risk of developing type 2 diabetes in the general population: A targeted evidence-based review

Genetics in Medicine

Volumn 15, Issue 8, 2013, Pages 600-611

  Palomaki, Glenn E ^a   Melillo, Stephanie ^b,c   Marrone, Michael ^b,d,e   Douglas, Michael P ^b,d  

^a BROWN UNIVERSITY   (United States)

^b NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d McKing Consulting Corp   (United States)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Clinical utility; Clinical validity; Evidence based review; Genomic panels; Type 2 diabetes

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; GLUCOSE; HEMOGLOBIN A1C; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PLACEBO; TRANSCRIPTION FACTOR 7 LIKE 2;

ALLELE; BARIATRIC SURGERY; BODY MASS; ENVIRONMENTAL FACTOR; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC PREDISPOSITION; GENETIC RISK; GENOMIC PANEL; GENOTYPE; GLUCOSE BLOOD LEVEL; HEREDITY; HIGH RISK POPULATION; HUMAN; LIFESTYLE MODIFICATION; LOW CARBOHYDRATE DIET; LOW FAT DIET; MARKER GENE; META ANALYSIS (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PREDICTIVE VALUE; REPRODUCIBILITY; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW (TOPIC); VALIDITY; WEIGHT REDUCTION;

ADULT; ALLELES; DIABETES MELLITUS, TYPE 2; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; META-ANALYSIS AS TOPIC; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; TRANSCRIPTION FACTOR 7-LIKE 2 PROTEIN;

EID: 84881352698     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1038/gim.2013.8     Document Type: Review

References (49)

1. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States 2011. CDC: Atlanta, GA, 2011.
2. Knowler WC, Barrett-Connor E, Fowler SE, et al.; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346: 393-403. (Pubitemid 34437694)
3. Florez JC, Jablonski KA, Bayley N, et al.; Diabetes Prevention Program Research Group. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med 2006;355: 241-250. (Pubitemid 44079339)
4. Moore AF, Jablonski KA, McAteer JB, et al.; Diabetes Prevention Program Research Group. Extension of type 2 diabetes genome-wide association scan results in the diabetes prevention program. Diabetes 2008;57: 2503-2510.
5. Florez JC, Jablonski KA, Sun MW, et al.; Diabetes Prevention Program Research Group. Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone. J Clin Endocrinol Metab 2007;92: 1502-1509. (Pubitemid 46556431)
6. Florez JC, Jablonski KA, Kahn SE, et al. Type 2 diabetes-associated missense polymorphisms KCNJ11 E23K and ABCC8 A1369S influence progression to diabetes and response to interventions in the Diabetes Prevention Program. Diabetes 2007;56: 531-536.
7. Jablonski KA, McAteer JB, de Bakker PI, et al.; Diabetes Prevention Program Research Group. Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle intervention in the diabetes prevention program. Diabetes 2010;59: 2672-2681.
8. Fisher E, Boeing H, Fritsche A, Doering F, Joost HG, Schulze MB. Whole-grain consumption and transcription factor-7-like 2 (TCF7L2) rs7903146: gene-diet interaction in modulating type 2 diabetes risk. Br J Nutr 2009;101: 478-481.
9. Grau K, Cauchi S, Holst C, et al. TCF7L2 rs7903146-macronutrient interaction in obese individuals' responses to a 10-wk randomized hypoenergetic diet. Am J Clin Nutr 2010;91: 472-479.
10. Valdez R. Detecting undiagnosed type 2 diabetes: family history as a risk factor and screening tool. J Diabetes Sci Technol 2009;3: 722-726.
11. Harrison TA, Hindorff LA, Kim H, et al. Family history of diabetes as a potential public health tool. Am J Prev Med 2003;24: 152-159. (Pubitemid 36144093)
12. Kobberling J, Tillil H. Empirical risk figures for first degree relatives of non-insulin dependent diabetics. In: Kobberling J, Tillil H eds. The Genetics of Diabetes Mellitus. Academic Press: London, 1982: 201-209.
13. Teutsch SM, Bradley LA, Palomaki GE, et al.; EGAPP Working Group. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group. Genet Med 2009;11: 3-14.
14. Haddow JE, Palomaki GE. ACCE: a model process for evaluating data on emerging genetic tests. In: Khoury M, Little J, Burke W (eds). Human Genome Epidemiology: A Scientific Foundation for Using Genetic Information to Improve Health and Prevent Disease. Oxford University Press: Oxford, 2003: 217-233.
15. Ge D, Dong Y, Wang X, Treiber FA, Snieder H. The Georgia Cardiovascular Twin Study: influence of genetic predisposition and chronic stress on risk for cardiovascular disease and type 2 diabetes. Twin Res Hum Genet 2006;9: 965-970. (Pubitemid 46093787)
16. Chambers EC, Heshka S, Gallagher D, Wang J, Pi-Sunyer FX, Pierson RN Jr. Serum magnesium and type-2 diabetes in African Americans and Hispanics: a New York cohort. J Am Coll Nutr 2006;25: 509-513. (Pubitemid 46175666)
17. Yu W, Wulf A, Yesupriya A, Clyne M, Khoury MJ, Gwinn M. HuGE Watch: tracking trends and patterns of published studies of genetic association and human genome epidemiology in near-real time. Eur J Hum Genet 2008;16: 1155-1158.
18. Palomaki GE, Melillo S, Neveux L, et al. Use of genomic profiling to assess risk for cardiovascular disease and identify individualized prevention strategies-a targeted evidence-based review. Genet Med 2010;12: 772-784.
19. American Diabetes Association. Standards of medical care in diabetes - 2012. Diabetes Care 2012;35(suppl 1):S11-S63.
20. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327: 557-560. (Pubitemid 37088507)
21. Ioannidis JP, Boffetta P, Little J, et al. Assessment of cumulative evidence on genetic associations: interim guidelines. Int J Epidemiol 2008;37: 120-132. (Pubitemid 351228620)
22. Janssens AC, van Duijn CM. Five genetic variants associated with prostate cancer. N Engl J Med 2008;358:2739; author reply 2741. (Pubitemid 351860879)
23. Fan X, Felsovalyi A, Sivo S, Keenan S. SAS for Monte Carlo Studies: A Guide for Quantitative Researchers. SAS Publishing, 2002, http://support.sas. com/ publishing/.
24. Yu W, Gwinn M, Clyne M, Yesupriya A, Khoury MJ. A navigator for human genome epidemiology. Nat Genet 2008;40: 124-125.
25. Voight BF, Scott LJ, Steinthorsdottir V, et al.; MAGIC investigators; GIANT Consortium. Twelve type 2 diabetes susceptibility loci identified through largescale association analysis. Nat Genet 2010;42: 579-589.
26. Dupuis J, Langenberg C, Prokopenko I, et al.; DIAGRAM Consortium; GIANT Consortium; Global BPgen Consortium; Anders Hamsten on behalf of Procardis Consortium; MAGIC investigators. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet 2010;42: 105-116.
27. Fonseca VA. Identification and treatment of prediabetes to prevent progression to type 2 diabetes. Clin Cornerstone 2007;8: 10-18; discussion 19.
28. Fonseca VA. Identification and treatment of prediabetes to prevent progression to type 2 diabetes. Clin Cornerstone 2008;9: 51-59; discussion 60.
29. Gwinn M, Grossniklaus DA, Yu W, et al. Horizon scanning for new genomic tests. Genet Med 2011;13: 161-165.
30. Saxena R, Voight BF, Lyssenko V, et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 2007;316: 1331-1336. (Pubitemid 46871653)
31. Waters KM, Stram DO, Hassanein MT, et al. Consistent association of type 2 diabetes risk variants found in Europeans in diverse racial and ethnic groups. PLoS Genet 2010;6:e.1001078.
32. Zeggini E, Scott LJ, Saxena R, et al.; Wellcome Trust Case Control Consortium. Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet 2008;40: 638-645. (Pubitemid 351601209)
33. Wang H, Dou KF, Yang XJ, et al. [A case report of simultaneous liver, pancreasduodenum, and kidney transplantation in a patient with post-hepatitic cirrhosis combined with uremia and insulin-dependent diabetes related to chronic pancreatitis]. Zhonghua Yi Xue Za Zhi 2006;86: 2421-2424. (Pubitemid 44822883)
34. Personalized Medical Genomic Profile (PMGP) https://www.bcm.edu/ geneticlabs/test-detail.cfm?testcode=7000 (2012).
35. Hung YJ, Kuo SW, Wang CH, Chang HY, Hsieh SH, Landen H. Postmarketing surveillance of acarbose treatment in Taiwanese patients with type 2 diabetes mellitus. Clin Drug Investig 2006;26: 559-565. (Pubitemid 44411331)
36. Kim S, Misra A. SNP genotyping: technologies and biomedical applications. Annu Rev Biomed Eng 2007;9: 289-320. (Pubitemid 350246659)
37. Ragoussis J. Genotyping technologies for genetic research. Annu Rev Genomics Hum Genet 2009;10: 117-133.
38. Pompanon F, Bonin A, Bellemain E, Taberlet P. Genotyping errors: causes, consequences and solutions. Nat Rev Genet 2005;6: 847-859.
39. Mihaescu R, van Hoek M, Sijbrands EJ, et al. Evaluation of risk prediction updates from commercial genome-wide scans. Genet Med 2009;11: 588-594.
40. Wang J, Kuusisto J, Vänttinen M, et al. Variants of transcription factor 7-like 2 (TCF7L2) gene predict conversion to type 2 diabetes in the Finnish Diabetes Prevention Study and are associated with impaired glucose regulation and impaired insulin secretion. Diabetologia 2007;50: 1192-1200. (Pubitemid 46701561)
41. Lyssenko V, Jonsson A, Almgren P, et al. Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med 2008;359: 2220-2232.
42. Talmud PJ, Hingorani AD, Cooper JA, et al. Utility of genetic and non-genetic risk factors in prediction of type 2 diabetes: Whitehall II prospective cohort study. BMJ 2010;340:b4838.
43. Meigs JB, Shrader P, Sullivan LM, et al. Genotype score in addition to common risk factors for prediction of type 2 diabetes. N Engl J Med 2008;359: 2208-2219.
44. de Miguel-Yanes JM, Shrader P, Pencina MJ, et al.; MAGIC Investigators; DIAGRAM+ Investigators. Genetic risk reclassification for type 2 diabetes by age below or above 50 years using 40 type 2 diabetes risk single nucleotide polymorphisms. Diabetes Care 2011;34: 121-125.
45. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008;27: 157-172; discussion 207. (Pubitemid 351193639)
46. Dixon JB, Murphy DK, Segel JE, Finkelstein EA. Impact of laparoscopic adjustable gastric banding on type 2 diabetes. Obes Rev 2012;13: 57-67.
47. Hindle AK, Brody F, Tevar R, et al. TCF7L2 expression in diabetic patients undergoing bariatric surgery. Surg Endosc 2009;23: 700-704.
48. Mihaescu R, van Zitteren M, van Hoek M, et al. Improvement of risk prediction by genomic profiling: reclassification measures versus the area under the receiver operating characteristic curve. Am J Epidemiol 2010;172: 353-361.
49. Hlatky MA, Greenland P, Arnett DK, et al.; American Heart Association Expert Panel on Subclinical Atherosclerotic Diseases and Emerging Risk Factors and the Stroke Council. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 2009;119: 2408-2416.